Aurinia Pharmaceuticals opened higher at $16.23, compared with its previous close of $16.21. In the last trading session, the stock traded between $16.15 and $16.44. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aurinia Pharmaceuticals is now worth
$ 56.07
Resulting in a loss of
$ 43.93 (43.93%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.03%)
Day High
$16.44
Day Low
$16.15
Day Open
$16.23
Prev Close
$16.21
Volume
4,90,614
1W Return
-5.37%
1M Return
-2.16%
3M Return
5.52%
6M Return
3.09%
1Y Return
3.35%
Fundamentals
Market Cap ($ Mn)
2,171
PE Ratio
7.15
PB Ratio
3.52
PEG Ratio
0.02
ROE
71.44%
ROCE
21.65%
EPS (TTM)
$0.24
Investment Returns
1 Week
-5.37%
1 Month
-2.16%
3 Months
5.52%
6 Months
3.09%
9 Months
11.68%
Financials
Quarterly
All values in $ Mn
62.5
Mar 25
70.0
Jun 25
73.5
Sep 25
77.1
Dec 25
83.2
Jun 26
83.7
Sep 26
Updates
2Nov
RBC Capital raises Aurinia Pharmaceuticals price target to $18
RBC Capital raised the price target for Aurinia Pharmaceuticals from $16 to $18. Analyst Douglas Miehm maintained a Sector Perform rating on the stock. The rating indicates the stock is expected to perform in line with its sector.
10 days ago
30Oct
Aurinia Pharmaceuticals raises FY26 sales guidance to $325M-$330M
Aurinia Pharmaceuticals raised FY26 sales guidance to $325.000 million-$330.000 million. Previous FY26 guidance was $315.000 million-$325.000 million. New guidance remains below the $330.261 million consensus estimate. Q3 sales grew 13.93% YoY to $83.699 million.
13 days ago
21Oct
TD Cowen maintains Buy on Aurinia Pharmaceuticals, lifts price target to $18
TD Cowen maintains Buy rating on Aurinia Pharmaceuticals. Price target raised from $17 to $18. Analyst Stacy Ku issued the revised recommendation.
22 days ago
20Aug
Aurinia settles with Teva, blocking generic voclosporin launch until Dec 2036
Aurinia settled patent litigation with Teva, barring generic voclosporin launch until Dec 7, 2036. Teva stipulated Aurinia's patents expiring in Dec 2037 are valid and enforceable. AUPH shares rose 2.66% to $16.60 in premarket trading on Thursday. Litigation continues against other generic makers including Dr. Reddy's and Sandoz. Stock up 34.64% over past year, trading above 20-day SMA of $15.31.
2mo ago
6Jul
Aurinia initiates PRESERVE study for lupus nephritis
Aurinia Pharmaceuticals Inc. has launched the PRESERVE study, a Phase 4 trial evaluating LUPKYNIS combined with belimumab, obinutuzumab, or anifrolumab for lupus nephritis. The study targets 150 patients across 50 US sites, aiming to improve complete renal response rates.
